Title
Category
Credits
Event date
Cost
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
The advent of SGLT-2 inhibitors and GLP-1 RAs to address cardiorenal risk in patients with and without type 2 diabetes, has opened up new avenues of prevention and treatment. However, individualizing the vast amount of evidence to patient care remains challenging. During this case, you will have a chance to explore treatment decisions to decrease overall cardiorenal risk in a complex patient, accompanied by expert commentary and brief review of evidence with SGLT-2is and GLP-1 RAs across cardiovascular outcomes trials.
  • CMHC
  • ABIM MOC and AMA PRA Category 1 Credit
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit
  • ANCC
  • CDE
  • Participation
$0.00
GLP-1 RAs have carved an important role in the management of patients with type 2 diabetes (T2D), not only in glycemic control, but also in reducing cardiovascular and renal risk. The evolving evidence with GLP-1 RA in this setting has led to important studies and guideline changes, all with significant implications for patient management. This interactive infographic activity will walk you through these updates by using high-impact visuals to summarize the evidence, as well as added expert perspectives.